The present invention relates to the treatment of cancer using combination therapy comprising a dual insulin receptor substrate modulator (IRS) and signal transducer and transcription activator 3 (stat3), in combination with (i) a protein modulator. kinase (pk) selected from an epidermal growth factor inhibitor (egfr inhibitor) and egfr antibody； (ii) a rapamycin mammalian target inhibitor (mtor)； (iii) a mitogen activated protein kinase (mek) inhibitor； (iv) a mutated b-raf inhibitor； (v) a chemotherapeutic agent such as gemcitabine, 5-fu, irinotecan and oxaliplatin； and (vi) certain combinations thereof. the combination may be used to treat a tumor that has developed resistance to an egfr inhibitor, egfr antibody, mtor inhibitor, mek inhibitor, mutated b-raf inhibitor, chemotherapeutic agents, and certain combinations thereof, or to prevent acquired resistance of a tumor to any of said inhibitors or agents, or to prevent tumor recurrence after cessation of treatment with any of said inhibitors or agents or a combination thereof. The combination provides a therapeutic effect that is at least additive and is preferably synergistic. The present invention further relates to the treatment of cancer using combination therapy comprising a dual irs and stat3 modulator in combination with an immunotherapy agent. The combination can be used to sensitize a tumor to immunotherapy.a presente invenção se refere ao tratamento de câncer usando terapia de combinação compreendendo um modulador duplo de substrato de receptor de insulina (irs) e transdutor de sinal e ativador da transcrição 3 (stat3), em combinação com (i) um modulador de uma proteína quinase (pk) selecionada dentre um inibidor do fator de crescimento epidérmico (inibidor de egfr) e anticorpo egfr； (ii) um inibidor do alvo de mamíferos da rapamicina (mtor)； (iii) um inibidor da proteína quinase ativada por mitógeno (mek)； (iv) um inibidor de b-raf mutado； (v) um agente quimioterápico como gemcitabina, 5-fu, irinoteca
